Weight Loss Injectables

Semaglutide works by mimicking the natural GLP-1 hormone, which regulates appetite and blood sugar levels. It stimulates insulin release, when necessary, reduces glucagon production to prevent excess sugar, and slows gastric emptying, to promote a feeling of fullness. 

Semaglutide:

* Decreases hunger and cravings while helping you feel full longer

* Decreases Glucose Spikes

* Decreases Insulin Resistance

* Increases Fat burning and weight loss.

Average weight loss of patients on Semaglutide is 15% of your body weight at 6 months. 

Tirzepatide is a medicine that helps treat obesity and type 2 diabetes by a unique mechanism of action. It binds to both the glucagon-like peptide-1 receptor (GLP-1) and the glucose-dependent insulinotropic polypeptide receptor (GIP). The following is how tirzepatide works:

Tirzepatide Activates the GLP-1 Receptor: GLP-1 is a natural hormone that the gut produces in response to food intake. The GLP-1 receptor has various positive effects when activated:

*  Stimulates pancreatic insulin secretion, which aids in blood sugar control.

*  Inhibits the release of glucagon, another hormone that elevates blood sugar levels.

*  Delays stomach emptying, resulting in decreased appetite and a sensation of fullness.

*  Has the potential to improve insulin sensitivity in cells.

Patients who have taken Tirzepatide have lost up to 20% of their body weight in 6 months.

Retatrutide is revolutionary new drug currently in phase 3 of clinical trials on its way to FDA approval that takes action on three receptors in the body that leads to weight loss. These three receptors are GLP-1, GIP, and Glucagon. This can have additional benefits on appetite control and fat burning.

It is important to know that it is currently NOT FDA approved. However, it has shown incredible results already in its Phase 2 clinical trials.

After just 24 weeks, patients who received 12mg of retatrutide saw up to 17.5% weight loss. After 48 weeks, 24% weight loss. 1 in 4 patients lost 30% or more of their body weight. Weight lost over an ll month period was an average of 60 pounds. Weight loss also appeared to occur sooner than other weight loss injectable medicines. Thus far, it has a similar side effect and safety profile as Semaglutide and Tirzepatide.

Fat Burner Lipo-C is often referred to as "lipotropic” injections, are a type of treatment used primarily to aid in weight loss and fat reduction. These injections are composed of a blend of compounds that are believed to help the body metabolize fat more efficiently. 

They are notable for their content of Vitamin B12, along with other lipotropic agents like choline, methionine, and inositol (MIC).

The primary aim of these injections is to aid in the process of fat metabolism and overall weight loss, with a significant emphasis on the role of Vitamin B12.

These injections also include a complex of other B vitamins to aid in overall health and weightloss. 

NAD+ stands for nicotinamide adenine dinucleotide, also commonly known as NAD, and this compound can come in two forms: NAD+ and NADH (the '+' refers to the oxidized form of NAD, while NADH refers to the reduced form). 

Coenzymes like NAD bind to other enzymes to help initiate and accelerate actions that are essential to our body's healthy function.

Benefits of NAD+: Reverses visible signs of aging, increases energy levels, enhances mood and clarity, reduces fatigue, restores muscle function, reduces inflammation, prevents and corrects damage to DNA, helps optimize metabolism for better fat burning. 

Cagrilintide is a synthetic analogue of amylin, a naturally occurring hormone produced in the pancreas alongside insulin. Amylin plays a key role in controlling blood sugar levels, regulating appetite, and signaling satiety after eating. 

Developed to be long-acting and highly effective, Cagrilintide was designed to enhance the effects of GLP-1 receptor agonists, such as semaglutide or tirzepatide, which are widely used in weight loss and diabetes management therapies. 

Glucagon-like peptide-1 (GLP-1) analogs increase insulin secretion, suppress glucagon release, and slow gastric emptying, thereby contributing to improved glycemic control and significant weight loss in patients. The combination of these therapies has shown tremendous potential for not only reducing weight but also improving metabolic health markers.